Citius Pharma's Cancer Drug Is Gaining Traction Fast — But Can Sales Outrun a Cash Crisis?

Shares of Citius Pharmaceuticals surged 10.4% to $0.69 after its oncology subsidiary disclosed that its sole commercial product — a targeted therapy for a rare skin cancer — is spreading rapidly through U.S. treatment centers. During the quarter ended June 30, 2026, new institutions ordering the drug rose 78% compared with the prior quarter.

Vial orders from institutions through wholesalers climbed 31% in the same period. For a stock trading below a dollar, the question isn't whether the drug works — it's whether the revenue can scale quickly enough to keep the company alive.

• Hospitals Are Signing Up, But the Base Is Still Tiny. The drug is now available in 42 institutions, including academic oncology centers, leading NCCN institutions, and community infusion centers. That's meaningful growth off a small base — management says the expanded sales team will now target over 250 priority treatment centers.

The company recently added 21 commercial field professionals and eight medical science liaisons , all expected to be fully deployed by August 2026. More feet on the ground should widen the funnel, but 42 out of 250+ targets means the drug is still early in its rollout.

• Revenue Is Real, But the Burn Rate Is Brutal. In its first six months (only four months of actual selling), Citius Oncology generated $5.6 million in net revenue at roughly 80% gross margins. That sounds healthy — until you see the other side of the ledger. The parent company posted a $37.5 million net loss, with just $4.6 million in cash and negative working capital of ~$23.3 million , leading management itself to flag "substantial doubt" about continuing operations beyond November 2026 without new financing.

• A Manufacturing Setback Adds Risk. The drug's bulk supplier terminated its agreement and exited production entirely, triggering roughly $20.1 million in termination costs and a $19.7 million cancellation fee.

Inventory on hand — valued at $22.7 million as of March — provides a buffer , but finding a new manufacturer while scaling sales is a high-wire act.

• The Market Opportunity Exists — If They Can Reach It. Management estimates the initial addressable market exceeds $400 million and is "underserved by existing therapies."

Orphan drug status and pending combination-therapy patents offer competitive protection. But at its current run rate, Citius is capturing a tiny fraction. Investors are betting the account growth curve bends sharply upward. The stock's move says optimism is building; the balance sheet says the clock is ticking.